But that gain was more than offset by the lesser benefit from excluding
the most illiquid stocks.
Not exact matches
As you can see the price does move just like
most stocks, and the average daily volume is over 1 million per day, so it's not really an
illiquid stock.
* Finally, MediciNova is an extremely
illiquid stock that
most Avigen stockholders would find difficult to trade in the open market without significantly depressing the price, which warranted concessions.
Of course, we're already seeing this phenomenon in terms of investor sentiment & the markets... and conversely, small cap / value
stocks are now being generally neglected as far too difficult &
illiquid a proposition for
most such buyers.
(
Most bondholders have no desire to hold equity at all, much less an
illiquid penny
stock, thus the 54 % lockup).
That difference was
most pronounced for funds that trade
illiquid securities; it didn't show up in funds that primarily trade
stocks or futures contracts, which have active markets and easily obtained prices.
Most have rarely lost money in this market and only a few have ever experienced the frustration of being trapped in an
illiquid asset like the
stock of a private company.